Dixon Technologies: Vivo JV could lift FY27 volumes

Dixon Technologies has told investors it is confident of receiving PN3 approval for its proposed joint venture (JV) with Vivo, a key regulatory step that would allow the partnership to start manufacturing smartphones in India. Management discussed the timeline at an Investec conference and in a post-earnings call, outlining how the Vivo arrangement could materially add to volumes from FY26-27 and support a broader expansion plan across electronics manufacturing services (EMS).

The approvals matter because the Vivo JV has been positioned as a major incremental volume driver for Dixon’s mobile business. Alongside this, the company has flagged backward integration, new products, exports, and entry into industrial EMS as parallel growth levers.

What PN3 approval means for Dixon and Vivo

PN3 approval is a compulsory multi-ministry clearance required when entities from neighbouring countries such as China invest in India, including through joint ventures. Dixon has said it is awaiting PN3 approval for the Vivo JV and also for its proposed display joint venture with China’s HKC Corp.

At the Investec conference, Dixon’s management reiterated confidence about securing PN3 clearance for Vivo. Separate commentary in the provided material indicates the approval is expected “within few months,” and another assumption set factors Vivo approval coming through during 1QFY27.

Production timeline after approval

One operational detail highlighted is the post-approval lead time. After regulatory approval, Dixon is expected to need another 45-60 days to commence production.

In a post-earnings interaction, Atul B. Lall, CEO and managing director, said Dixon expects to operationalise its Noida facility under the Vivo JV by the end of the June quarter of the next financial year. The facility under construction is expected to have an initial capacity of 18 million units.

How big the Vivo volume opportunity could be

The article material contains multiple, broadly aligned indicators of the opportunity size:

• At the Investec conference, management indicated the JV could manufacture about two-thirds of Vivo’s India sales, with Vivo’s annual mobile sales cited at 35 million units.
• In another management statement linked to the term sheet, Vivo’s total output is described as around 28-30 million units, with 67% expected to be done under the JV, translating into about 18-20 million units.

These figures point to Dixon’s potential role as a large manufacturing partner for Vivo in India once PN3 approval is received and the Noida unit ramps up.

Dixon’s smartphone volume outlook for FY26 to FY28

Dixon’s guidance and external factoring in the provided text set out multiple checkpoints for volumes:

• FY26 mobile volumes expected at 40-42 million units.
• FY27 guidance at 55-60 million units, explicitly including Vivo and the Longcheer JV.
• A separate set of forecasts factors smartphone volumes of 51.8 million and 56.3 million units for FY27 and FY28, assuming base volumes decline in FY27 before new client additions and Vivo volumes add support.

Management also indicated that for FY27, mobile volumes excluding Vivo are expected to broadly match FY26 levels, suggesting the growth step-up is closely tied to incremental programmes such as the Vivo partnership.

Backward integration and margin trajectory

Dixon has highlighted backward integration as a strategic priority, with benefits expected to begin “kicking in” from 2HFY27. In the same context, the material factors in overall EBITDA margins of:

• 3.6% for FY27
• 4.3% for FY28

The linkage is clear in the company’s stated strategy: building scale, improving operational efficiency, extending customer relationships, focusing on backward integration, and diversification to manage the operating environment.

Financial outlook: growth assumptions cited

Based on the volume and scale-up assumptions across segments, the provided material expects a CAGR over FY25-28 of:

• 28% in revenue
• 32% in EBITDA
• 30% in PAT

The same outlook reiterates EBITDA margins of 3.6% in FY27 and 4.3% in FY28, with Vivo approval assumed during 1QFY27.

Other growth levers discussed: IT hardware, industrial EMS, exports

Beyond mobiles, Dixon has described multiple initiatives:

• Backward integration (upstream manufacturing capabilities)
• New product development
• Export expansion (company says it is in talks with customers)
• Entry into industrial EMS

On IT hardware, management commentary in the provided text cites an FY26 revenue target of ₹1,200-1,300 crore, with a ramp to ₹4,000-5,000 crore in two years. The JV with Inventec is expected to start production by Q2 of the next fiscal year.

Display JV with HKC and capacity plans

Dixon has also said it is awaiting PN3 approval for its JV with HKC Corp. for display manufacturing. Capacity targets cited include:

• Phase 1 capacity: 24 million smartphone displays and 2 million notebook displays per annum
• Phase 2 capacity: 60 million smartphone displays, 2 million TV displays, and 1 million automotive displays per annum

The provided material also notes that margins for the display business are expected to be in “higher double digits,” as per the stated plan.

Key numbers at a glance

Stock performance snapshot cited

Why the Vivo JV approval is a key near-term trigger

The timelines and volume guidance show that PN3 approval is central to Dixon’s FY27 volume step-up. The company’s own guidance for FY27 (55-60 million units including Vivo and Longcheer) and the externally factored FY27-28 volumes (51.8 million and 56.3 million units) both assume meaningful support from new programmes.

Separately, the expected margin improvement from 3.6% to 4.3% between FY27 and FY28 has been linked to backward integration benefits beginning from 2HFY27. That sequence places execution milestones in a tight window: approvals, production commencement after 45-60 days, and ramp-up into a period where cost and component strategies are expected to start reflecting in profitability metrics.

Conclusion

Dixon Technologies has reiterated confidence that PN3 approval for the Vivo JV will come through, after which production is expected to begin in roughly 45-60 days. Management has also pointed to a broader growth agenda spanning backward integration, IT hardware scale-up, exports, and a potential industrial EMS entry. Investors are likely to track PN3 approval timelines, the Noida facility ramp-up, and the company’s stated FY27 volume band of 55-60 million units that includes contributions from Vivo and the Longcheer JV.